Cat. No.: HY-N0593

Deoxycholic acid

(Synonyms: Cholanoic acid; Desoxycholic acid)

27 Cited Publications

Customer Review

Based on 27 publication(s) in Google Scholar

Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 83-44-3
Formula: C₂₄H₄₀O₄
Molecular Weight:392.57

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Deoxycholic acid Chemical Structure

CAS No.: 83-44-3

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (27)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5^[1]^[2].

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	1.25 μM Compound: 7, DCA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
HEK293	EC₅₀	50 μM Compound: 4, DCA	Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay	[PMID: 22583617]
HEK-293T	EC₅₀	>150 μM Compound: DCA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	>50 μM Compound: DCA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HepG2	IC₅₀	>100 μM Compound: DCA	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 28688958]
HET-1A	CC₅₀	257 μM Compound: 10 DCA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-29	IC₅₀	>80 μM Compound: DCA	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 27448915]
HuTu80	IC₅₀	82.9 μM Compound: DCA	Antiproliferative activity against human HuTu 80 cells after 24 hrs by MTT assay Antiproliferative activity against human HuTu 80 cells after 24 hrs by MTT assay	[PMID: 28688958]
KB 3-1	IC₅₀	>100 μM Compound: DCA	Antiproliferative activity against human KB3-1 cells after 24 hrs by MTT assay Antiproliferative activity against human KB3-1 cells after 24 hrs by MTT assay	[PMID: 28688958]
PC-3M	IC₅₀	>80 μM Compound: DCA	Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay	[PMID: 27448915]

In Vitro

Deoxycholic acid (DCA) (100 μM) induces the production of gastric cancer cell line MGC803 resistant to acidified bile acids and enhances their survival and proliferation activity under bile acid stress^[2].
Deoxycholic acid (DCA) (100 μM)-induced resistant cells shows altered morphology, significantly elevated telomerase activity, better cell viability and reduces apoptosis compared to normal MGC803 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 83-44-3
Appearance Solid
Molecular Weight 392.57
Formula C₂₄H₄₀O₄
Color White to off-white
SMILES

C[C@@]1([C@@]2([H])[C@H](C)CCC(O)=O)[C@](CC2)([H])[C@@](CC[C@@]3([H])[C@@]4(CC[C@@H](O)C3)C)([H])[C@]4([H])C[C@@H]1O
Synonyms

Cholanoic acid; Desoxycholic acid
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (27)

All RT-PCRBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Nature

Structure and mechanism of the human bile acid transporter OSTα-OSTβ. [Abstract]

2026 Mar;651(8104):251-259. PMID: 41606314
Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Cell Res

Virus-induced accumulation of intracellular bile acids activates the TGR5-β-arrestin-SRC axis to enable innate antiviral immunity. [Abstract]

2019 Mar;29(3):193-205. PMID: 30651583

Deoxycholic acid purchased from MedChemExpress. Usage Cited in: Cell Res. 2019 Mar;29(3):193-205. [Abstract]

Virus-triggered accumulation of intracellular bile acids (BAs) promotes cellular antiviral response. Effects of BAs on virus-induced transcription of antiviral genes. Raw264.7 cells were infected with HSV-1 or SeV for 30 min and treated with Lithocholic acid (LCA) (0.1 mM), Chenodeoxycholic Acid (CDCA) (0.1 mM) or Deoxycholic acid (DCA) (0.1 mM) for 6 h before qPCR analysis of the indicated mRNA levels.

Deoxycholic acid purchased from MedChemExpress. Usage Cited in: Cell Res. 2019 Mar;29(3):193-205. [Abstract]

Examination of intracellular bile acids (BA) levels after cells were treated with exogenous BAs. Raw264.7 cells were infected with HSV-1 or SeV for 30 min and treated with Lithocholic acid (LCA) (0.1 mM), Chenodeoxycholic Acid (CDCA) (0.1 mM) or Deoxycholic acid (DCA) (0.1 mM) for 6 h before BA assays were performed.
Nat Cell Biol

Genome-wide screening of NEAT1 regulators reveals cross-regulation between paraspeckles and mitochondria. [Abstract]

2018 Oct;20(10):1145-1158. PMID: 30250064
Cell Host Microbe

Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease. [Abstract]

2025 Aug 19:S1931-3128(25)00291-4. PMID: 40848719
Cell Host Microbe

Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. [Abstract]

2025 Jun 11;33(6):915-931.e9. PMID: 40441145
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Feb 3:e2411719. PMID: 39899681

Deoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Microbiome

Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites. [Abstract]

2019 Mar 20;7(1):43. PMID: 30890187
Gut Microbes

Antibiotic cocktail-induced changes in gut microbiota drive alteration of bile acid metabolism to restrain Th17 differentiation through the FXR-NLRP3 axis. [Abstract]

2025 Dec 31;17(1):2582944. PMID: 41305918
Nat Cardiovasc Res

The gut microbiota-bile acid-TGR5 axis orchestrates platelet activation and atherothrombosis. [Abstract]

2025 Apr 11. PMID: 40217125
Mater Today Bio

Living bacterial reactor potently activates tumor immunogenic ferroptosis via cysteine depletion and photothermal therapy. [Abstract]

2026 Feb 1:37:102843. PMID: 41704298
Adv Healthc Mater

An Injectable Liposome-Hydrogel Composite for Targeted Delivery of a Non-Lactylated Peptide to Rebalance Bone Metabolism in Hyperlipidemia. [Abstract]

2026 Feb 21:e05684. PMID: 41721628
Genes Dis

2026 Jan 24.
Int J Biol Macromol

Deoxycholic acid inhibits ASFV replication by inhibiting MAPK signaling pathway. [Abstract]

2024 May;266(Pt 1):130939. PMID: 38493816
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318
Chin Med J (Engl)

Therapeutic effect of metformin on reversing gastric intestinal metaplasia. [Abstract]

2025 Jun 16. PMID: 40518567
Cell Death Discov

TGR5-HNF4α axis contributes to bile acid-induced gastric intestinal metaplasia markers expression. [Abstract]

2020 Jul 6;6:56. PMID: 32655894
Cell Rep

Multilevel regulation of c-di-GMP biosynthesis by cAMP signaling increases Shigella sonnei fitness and pathogenicity in response to bile salts. [Abstract]

2025 Sep 17;44(10):116306. PMID: 40966079
Cancer Cell Int

SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia. [Abstract]

2019 Jan 31:19:24. PMID: 30733645

Deoxycholic acid purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2019 Jan 31:19:24. [Abstract]

The expression of CDX2, KLF4, HNF4α, and cadherin 17 is increased upon stimulation with DCA in a dose-dependent manner.

Deoxycholic acid purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2019 Jan 31:19:24. [Abstract]

The expression of CDX2, KLF4, HNF4α, and cadherin 17 is increased upon stimulation with DCA in a dose-dependent manner.

Deoxycholic acid purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2019 Jan 31:19:24. [Abstract]

Western blotting results indicated that the inhibition of SOX2 in bile acid-treated AGS cells is partially rescued in miR-21 knockdown AGS cells.
J Invest Dermatol

Bile Acids Improve Psoriasiform Dermatitis through Inhibition of IL-17A Expression and CCL20-CCR6-Mediated Trafficking of T Cells. [Abstract]

2022 May;142(5):1381-1390.e11. PMID: 34808237
Drug Metab Dispos

Tertiary Oxidation of Deoxycholate Is Predictive of CYP3A Activity in Dogs. [Abstract]

2021 May;49(5):369-378. PMID: 33674269
Biomedicines

The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia. [Abstract]

2025 Apr 4;13(4):874. PMID: 40299495
Aquaculture

2023 Sep 18, 740123.
Microb Pathog

Lithocholic acid exerts antiviral activity against porcine epidemic diarrhea virus by enhancing TGR5-mediated type III interferon production. [Abstract]

2026 Jan:210:108187. PMID: 41242567
J Pharm Biomed Anal

Integrating 16S rDNA sequencing analysis and targeted metabolomics to explore the mechanism of Xiexin Tang in treating atherosclerosis mice induced by high-fat diet. [Abstract]

2025 Jul 15:259:116760. PMID: 40014894
R Soc Open Sci

Ultra-performance liquid chromatography-tandem mass spectrometric method for quantitation of the recently Food and Drug Administration approved combination of vaborbactam and meropenem in human plasma. [Abstract]

2020 Jul 8;7(7):200635. PMID: 32874656
Laurea Magistrale in Biomedical Engineering, Politecnico di Milano

2019 Jun.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (254.73 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5473 mL

12.7366 mL

25.4732 mL

5 mM

0.5095 mL

2.5473 mL

5.0946 mL

10 mM

0.2547 mL

1.2737 mL

2.5473 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (6.37 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water

Solubility: 10 mg/mL (25.47 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

MGC803 cells are cultured in Roswell Park Memorial Institute media supplemented with 10% fetal calf serum and 100 U/mL Penicillin and 100 mg/mL Streptomycin. To generate MGC803-resistant cells, the pH value of the MGC803 culture medium is adjusted to the experimental conditions using the hydrochloric acid (A). The bile acids GCDA and Deoxycholic acid are diluted to optimal working concentrations of 100 μM (B) with culture medium, and the overall pH (A+B) is adjusted to pH 5.5, simulating the gastric environment. Initially, MGC803 cells are chronically exposed to acidified medium with bile acids (A+B) for 10 min every 24 h. The experimental time and conditions are optimized in our preliminary experiments, which show that 10 min is enough and does not result in cell damage. This procedure is repeated and it takes 60 weeks for the MGC803 cells to survive and proliferate under the exposure of A+B for 120 min. Control untreated cells are cultured in neutral RPMI medium at pH 7.4 in parallel to the resistant cells for 60 weeks. The morphological changes in MGC803 cells exposed to acidified bile acids (A+B) are documented at 30 and 60 weeks^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Somm E, et al. β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight. 2017 Apr 20;2(8). pii: 91809. [Content Brief]

[2]. Wang X, et al. Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in micedependent on c-Myc expression. Cancer Med. 2017 Apr;6(4):788-797. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5473 mL	12.7366 mL	25.4732 mL	63.6829 mL
	5 mM	0.5095 mL	2.5473 mL	5.0946 mL	12.7366 mL
	10 mM	0.2547 mL	1.2737 mL	2.5473 mL	6.3683 mL
	15 mM	0.1698 mL	0.8491 mL	1.6982 mL	4.2455 mL
	20 mM	0.1274 mL	0.6368 mL	1.2737 mL	3.1841 mL
	25 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	30 mM	0.0849 mL	0.4246 mL	0.8491 mL	2.1228 mL
	40 mM	0.0637 mL	0.3184 mL	0.6368 mL	1.5921 mL
	50 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2737 mL
	60 mM	0.0425 mL	0.2123 mL	0.4246 mL	1.0614 mL
	80 mM	0.0318 mL	0.1592 mL	0.3184 mL	0.7960 mL
	100 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL

Keywords

Deoxycholic acid

27 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Deoxycholic acid

GPCR/G Protein Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Food Additive Library

Food-Sourced Compound Library

Inactive Ingredient Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Bile Acids Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lipid Metabolite Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Deoxycholic acid

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (27)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Deoxycholic acid Related Classifications

Cat. No.: HY-N0593